1-20 of 27
Jeffrey A. Engelman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors

Kelli-Ann Monaco, Scott Delach, Jing Yuan, Yuji Mishina, Paul Fordjour, Emma Labrot, Daniel McKay, Ribo Guo, Stacy Higgins, Hui Qin Wang, Jinsheng Liang, Karen Bui, John Green, Peter Aspesi, Jessi Ambrose, Felipa Mapa, Lesley Griner, Mariela Jaskelioff, John Fuller, Kenneth Crawford, Gwynn Pardee, Stephania Widger, Peter S. Hammerman, Jeffrey A. Engelman, Darrin D. Stuart, Vesselina G. Cooke, Giordano Caponigro
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (7): 2061–2073.
https://doi.org/10.1158/1078-0432.CCR-20-2563
Published: 01 April 2021
View article titled, LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Open the PDF for LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors in another window
Includes: Supplementary data
Journal Articles

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Chen Liu, Hengyu Lu, Hongyun Wang, Alice Loo, Xiamei Zhang, Guizhi Yang, Colleen Kowal, Scott Delach, Ye Wang, Silvia Goldoni, William D. Hastings, Karrie Wong, Hui Gao, Matthew J. Meyer, Susan E. Moody, Matthew J. LaMarche, Jeffrey A. Engelman, Juliet A. Williams, Peter S. Hammerman, Tinya J. Abrams, Morvarid Mohseni, Giordano Caponigro, Huai-Xiang Hao
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 342–354.
https://doi.org/10.1158/1078-0432.CCR-20-2718
Published: 04 January 2021
View article titled, Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Open the PDF for Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling in another window
Includes: Supplementary data
Journal Articles

NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263

Anahita Dastur, AHyun Choi, Carlotta Costa, Xunqin Yin, August Williams, Joseph McClanaghan, Max Greenberg, Justine Roderick, Neha U. Patel, Jessica Boisvert, Ultan McDermott, Mathew J. Garnett, Jorge Almenara, Steven Grant, Kathryn Rizzo, Jeffrey A. Engelman, Michelle Kelliher, Anthony C. Faber, Cyril H. Benes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (1): 312–324.
https://doi.org/10.1158/1078-0432.CCR-18-0867
Published: 03 January 2019
View article titled, NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Open the PDF for NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263 in another window
Includes: Supplementary data
Journal Articles

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

Kyung-A Song, Matthew J. Niederst, Timothy L. Lochmann, Aaron N. Hata, Hidenori Kitai, Jungoh Ham, Konstantinos V. Floros, Mark A. Hicks, Haichuan Hu, Hillary E. Mulvey, Yotam Drier, Daniel A.R. Heisey, Mark T. Hughes, Neha U. Patel, Elizabeth L. Lockerman, Angel Garcia, Shawn Gillepsie, Hannah L. Archibald, Maria Gomez-Caraballo, Tara J. Nulton, Brad E. Windle, Zofia Piotrowska, Sinem E. Sahingur, Shirley M. Taylor, Mikhail Dozmorov, Lecia V. Sequist, Bradley Bernstein, Hiromichi Ebi, Jeffrey A. Engelman, Anthony C. Faber
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (1): 197–208.
https://doi.org/10.1158/1078-0432.CCR-17-1577
Published: 02 January 2018
View article titled, Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
Open the PDF for Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM in another window
Includes: Supplementary data
Journal Articles

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea Fulton, Katherine R. Schultz, Emily Howe, Anna F. Farago, Ryan J. Sullivan, James R. Stone, Subba Digumarthy, Teresa Moran, Aaron N. Hata, Yukako Yagi, Beow Y. Yeap, Jeffrey A. Engelman, Mari Mino-Kenudson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (18): 4585–4593.
https://doi.org/10.1158/1078-0432.CCR-15-3101
Published: 15 September 2016
View article titled, <em>EGFR</em> Mutations and <em>ALK</em> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Open the PDF for <em>EGFR</em> Mutations and <em>ALK</em> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis in another window
Includes: Supplementary data
Journal Articles

Abstract A13: Development of a drug response assessment platform for biopsy-derived tumor models

David P. Kodack, Matthew Held, Leah Damon, Dana Lee, Melissa Parks, Richard Dicecca, Max Greenberg, Jeffrey A. Engelman, Cyril H. Benes
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): A13.
https://doi.org/10.1158/1557-3265.PDX16-A13
Published: 15 August 2016
View article titled, Abstract A13: Development of a drug response assessment platform for biopsy-derived tumor models
Journal Articles

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Tilak K. Sundaresan, Lecia V. Sequist, John V. Heymach, Gregory J. Riely, Pasi A. Jänne, Walter H. Koch, James P. Sullivan, Douglas B. Fox, Robert Maher, Alona Muzikansky, Andrew Webb, Hai T. Tran, Uma Giri, Martin Fleisher, Helena A. Yu, Wen Wei, Bruce E. Johnson, Thomas A. Barber, John R. Walsh, Jeffrey A. Engelman, Shannon L. Stott, Ravi Kapur, Shyamala Maheswaran, Mehmet Toner, Daniel A. Haber
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1103–1110.
https://doi.org/10.1158/1078-0432.CCR-15-1031
Published: 29 February 2016
View article titled, Detection of T790M, the Acquired Resistance <em>EGFR</em> Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
Open the PDF for Detection of T790M, the Acquired Resistance <em>EGFR</em> Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses in another window
Includes: Supplementary data
Journal Articles

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (17): 3924–3933.
https://doi.org/10.1158/1078-0432.CCR-15-0560
Published: 31 August 2015
View article titled, The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Open the PDF for The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies in another window
Includes: Supplementary data
Journal Articles

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Justin F. Gainor, Daniel S.W. Tan, Tomasso De Pas, Benjamin J. Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2745–2752.
https://doi.org/10.1158/1078-0432.CCR-14-3009
Published: 14 June 2015
View article titled, Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Open the PDF for Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib in another window
Includes: Supplementary data
Journal Articles

Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer

Brinda Alagesan, Gianmarco Contino, Alexander R. Guimaraes, Ryan B. Corcoran, Vikram Deshpande, Gregory R. Wojtkiewicz, Aram F. Hezel, Kwok-Kin Wong, Massimo Loda, Ralph Weissleder, Cyril Benes, Jeffrey A. Engelman, Nabeel Bardeesy
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (2): 396–404.
https://doi.org/10.1158/1078-0432.CCR-14-1591
Published: 14 January 2015
View article titled, Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
Open the PDF for Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer

Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, Naoya Fujita
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 166–174.
https://doi.org/10.1158/1078-0432.CCR-14-1385
Published: 05 January 2015
View article titled, Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Open the PDF for Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer in another window
Includes: Supplementary data
Journal Articles

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5686–5696.
https://doi.org/10.1158/1078-0432.CCR-14-1511
Published: 13 November 2014
View article titled, Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Open the PDF for Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib in another window
Includes: Supplementary data
Journal Articles

AACR Cancer Progress Report 2014

Carlos L. Arteaga, Peter C. Adamson, Jeffrey A. Engelman, Margaret Foti, Richard B. Gaynor, Susan G. Hilsenbeck, Paul J. Limburg, Scott W. Lowe, Elaine R. Mardis, Scott Ramsey, Timothy R. Rebbeck, Andrea L. Richardson, Eric H. Rubin, George J. Weiner
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (19_Supplement): S1–S112.
https://doi.org/10.1158/1078-0432.CCR-14-2123
Published: 01 October 2014
View article titled, AACR Cancer Progress Report 2014
Open the PDF for AACR Cancer Progress Report 2014 in another window
Includes: Supplementary data
Journal Articles

Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

Zhao Chen, Esra Akbay, Oliver Mikse, Tanya Tupper, Katherine Cheng, Yuchuan Wang, Xiaohong Tan, Abigail Altabef, Sue-Ann Woo, Liang Chen, Jacob B. Reibel, Pasi A. Janne, Norman E. Sharpless, Jeffrey A. Engelman, Geoffrey I. Shapiro, Andrew L. Kung, Kwok-Kin Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (5): 1204–1211.
https://doi.org/10.1158/1078-0432.CCR-13-1733
Published: 02 March 2014
View article titled, Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <em>ALK</em>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
Open the PDF for Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <em>ALK</em>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance in another window
Includes: Supplementary data
Journal Articles

Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2

Brent N. Rexer, Ritwik Ghosh, Archana Narasanna, Mónica Valeria Estrada, Anindita Chakrabarty, Youngchul Song, Jeffrey A. Engelman, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5390–5401.
https://doi.org/10.1158/1078-0432.CCR-13-1038
Published: 01 October 2013
View article titled, Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Open the PDF for Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2 in another window
Includes: Supplementary data
Journal Articles

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Justin F. Gainor, Anna M. Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M. Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y. Yeap, Gregory J. Riely, A. John Iafrate, Maria E. Arcila, Marc Ladanyi, Jeffrey A. Engelman, Dora Dias-Santagata, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4273–4281.
https://doi.org/10.1158/1078-0432.CCR-13-0318
Published: 31 July 2013
View article titled, <em>ALK</em> Rearrangements Are Mutually Exclusive with Mutations in <em>EGFR</em> or <em>KRAS</em>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
Open the PDF for <em>ALK</em> Rearrangements Are Mutually Exclusive with Mutations in <em>EGFR</em> or <em>KRAS</em>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer in another window
Journal Articles

Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Erin M. Coffee, Anthony C. Faber, Jatin Roper, Mark J. Sinnamon, Gautam Goel, Lily Keung, Wei Vivian Wang, Loredana Vecchione, Veerle de Vriendt, Barbara J. Weinstein, Roderick T. Bronson, Sabine Tejpar, Ramnik J. Xavier, Jeffrey A. Engelman, Eric S. Martin, Kenneth E. Hung
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (10): 2688–2698.
https://doi.org/10.1158/1078-0432.CCR-12-2556
Published: 12 May 2013
View article titled, Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of <em>BRAF<sup>V600E</sup></em> Colorectal Cancer
Open the PDF for Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of <em>BRAF<sup>V600E</sup></em> Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Characteristics of Lung Cancers Harboring NRAS Mutations

Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, Christine M. Lovly, Xi Chen, Charles M. Rudin, Teresa Moran, David Ross Camidge, Cindy L. Vnencak-Jones, Lynne Berry, Yumei Pan, Hidefumi Sasaki, Jeffrey A. Engelman, Edward B. Garon, Steven M. Dubinett, Wilbur A. Franklin, Gregory J. Riely, Martin L. Sos, Mark G. Kris, Dora Dias-Santagata, Marc Ladanyi, Paul A. Bunn, Jr, William Pao
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2584–2591.
https://doi.org/10.1158/1078-0432.CCR-12-3173
Published: 30 April 2013
View article titled, Characteristics of Lung Cancers Harboring <em>NRAS</em> Mutations
Open the PDF for Characteristics of Lung Cancers Harboring <em>NRAS</em> Mutations in another window
Includes: Supplementary data
Journal Articles

Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling

Ryan B. Corcoran, Kenneth E. Hung, Keith T. Flaherty, Adriano Piris, Jennifer A. Wargo, Jeffrey Settleman, Mari Mino-Kenudson, Jeffrey A. Engelman, Hiromichi Ebi, Alexa B. Turke, Erin M. Coffee, Michiya Nishino, Alexandria P. Cogdill, Ronald D. Brown, Patricia Della Pelle, Dora Dias-Santagata
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): PR8.
https://doi.org/10.1158/1078-0432.MECHRES-PR8
Published: 04 March 2013
View article titled, Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling
Open the PDF for Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling in another window
Journal Articles

Activation of PI3K Signaling in Merkel Cell Carcinoma

Valentina Nardi, Youngchul Song, Juan A. Santamaria-Barria, Arjola K. Cosper, Quynh Lam, Anthony C. Faber, Genevieve M. Boland, Beow Y. Yeap, Kristin Bergethon, Vanessa L. Scialabba, Hensin Tsao, Jeffrey Settleman, David P. Ryan, Darrell R. Borger, Atul K. Bhan, Mai P. Hoang, Anthony J. Iafrate, James C. Cusack, Jeffrey A. Engelman, Dora Dias-Santagata
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1227–1236.
https://doi.org/10.1158/1078-0432.CCR-11-2308
Published: 01 March 2012
View article titled, Activation of PI3K Signaling in Merkel Cell Carcinoma
Open the PDF for Activation of PI3K Signaling in Merkel Cell Carcinoma in another window
Includes: Supplementary data